Document:

EX-10.1

 Exhibit 10.1 

COOPERATION AGREEMENT 

This Cooperation Agreement (this “Agreement”) is made and entered into as of June 27, 2018, by and among RPM
International Inc., a Delaware corporation (the “Company”), Elliott Associates, L.P., a Delaware limited partnership (“Elliott Associates”), Elliott International, L.P., a Cayman Islands limited partnership
(“Elliott International”), and Elliott International Capital Advisors Inc., a Delaware corporation (together with Elliott Associates and Elliott International, the “Investors”). Capitalized terms used herein and not
otherwise defined have the meanings ascribed to them in paragraph 15 below. 
 RECITALS 

WHEREAS, the Company and the Investors have engaged in certain discussions concerning the Company; and 

WHEREAS, the Company and the Investors desire to enter into an agreement regarding the appointment and election of certain directors to the
Board of Directors of the Company (the “Board”) and certain other matters, in each case, on the terms and subject to the conditions set forth therein. 

NOW, THEREFORE, in consideration of and reliance upon the mutual covenants and agreements contained herein, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 
  

	 	1.	Director Appointments; Committees; Board Size. Effective as of the date hereof and upon the execution and delivery of this Agreement, the Board shall (a) increase the size of the Board to fourteen
(14) directors and (b) appoint Kirkland Andrews to serve as a Class I member of the Board (such Designee, the “Class I Designee”) and John Ballbach to serve as a Class II member of the
Board (such Designee, the “Class II Designee” and together with the Class I Designee, the “Designees” and each a “Designee”). 

 

	 	2.	Designee Agreements, Arrangements and Understandings. Each of the Investors represents, warrants and agrees that neither it nor any of its Affiliates (a) has made or will make any payments to any Designee in
connection with such Designee’s (i) agreement to serve or proposal of such person by the Investors as a Replacement Designee (as hereinafter defined) or (ii) service on the Board or any committee thereof or (b) has or will have
any agreement, arrangement or understanding, written or oral, with any Designee in connection with such Designee’s (i) agreement to serve or proposal of such person by the Investors as a Replacement Designee or (ii) service on the
Board or any committee thereof. 

  

	 	3.	 Designee Replacements. If, prior to the Trigger Date (as hereinafter defined), a Designee resigns, refuses
or is unable to serve or fulfill his or her duties as a director, then the Investors shall select a replacement director, subject to the consent of the Company (which consent shall not be unreasonably withheld or delayed), whom the Board shall have
reasonably determined qualifies as Independent and otherwise satisfies the Board membership criteria set forth in the 

	 	
Company’s Corporate Governance Guidelines, Categorical Independence Standards for Directors and the Governance and Nominating Committee Charter (a “Replacement Designee”).
Subject to paragraph 4 hereof, the Company shall cause such Replacement Designee to be appointed to the Board to serve the unexpired term of the departed Designee, and such Replacement Designee shall be considered a Designee and either the
Class I Designee or Class II Designee, as the case may be, for all purposes of this Agreement. 

  

	 	4.	Designee Information. As a condition to, and prior to, each Replacement Designee’s appointment to the Board, such proposed Replacement Designee shall have provided the Company with: (i) a completed
D&O questionnaire in the same form as the Company intends to use with all of its directors in advance of the 2018 Annual Meeting (as defined below) (with such changes as required by applicable law, rule, regulation or stock exchange rules or
listing standards); (ii) information reasonably requested by the Company of all of its directors in connection with assessing eligibility, independence and other criteria applicable to outside directors or satisfying compliance and legal
obligations; (iii) such written consents requested by the Company as may be reasonably necessary for the conduct of the Company’s standard vetting procedures conducted with respect to all
non-management directors and the execution of any documents reasonably required by the Company of non-management directors to assure compliance with the matters
referenced in paragraph 8 hereof; and (iv) such other information reasonably requested by the Company including, without limitation, an acknowledgment from such proposed Replacement Designee that he or she intends to serve for the full term for
which he or she is appointed or elected (including, in the case of any replacement of the Class II Designee prior to the 2018 Annual Meeting, any term to which he would be elected at the 2018 Annual Meeting). As a further condition to the
Company’s nomination of a Designee for election as a director at the Annual Meeting, such Designee shall have, reasonably promptly upon the request of the Company, provided the Company with: (i) an executed consent to be named as a nominee
in the Company’s proxy statement and to serve as a director if so elected and (ii) information requested by the Company from all non-management directors with respect to its proxy statement or other
filings under applicable law or stock exchange rules or listing standards. 

  

	 	5.	 Amendments to Certificate of Incorporation and By-Laws. Promptly
following the execution and delivery of this Agreement (and in no event later than July 17, 2018), the Board shall pass resolutions in the form attached hereto as Exhibit A proposing amendments (and recommending that the Company’s
stockholders vote in favor of such amendments at the Company’s 2018 Annual Meeting of Stockholders (including any postponement or adjournment thereof, the “2018 Annual Meeting”)) to the Company’s Amended and Restated
Certificate of Incorporation (as may be amended from time to time, the “Certificate of Incorporation”) and the Company’s Amended and Restated By-Laws (as may be amended from time to time,
the “By-Laws”), as applicable, to (i) eliminate Classes I, II and III of the Board so that the Board shall have no classification and (ii) reduce the threshold for action taken by
the Company’s stockholders to a 

  
 2 

	 	
simple majority (including, without limitation, Article VII of the Charter and Article XIV of the Bylaws) (collectively, the “Amendments”). For the avoidance of doubt, directors
elected at the 2018 Annual Meeting (and directors up for election at each annual meeting thereafter) will be elected for one-year term. 

 

	 	6.	2018 Annual Meeting. The Company shall include the Class II Designee (or the Replacement Designee) on its slate for election as directors of the Company at the 2018 Annual Meeting and shall use its
reasonable best efforts (which shall include the solicitation of proxies) to cause the election of the Class II Designee at the 2018 Annual Meeting (it being understood that such efforts shall not be less than the efforts used by the Company to
cause the election of any other Class II director nominee nominated by the Company at the 2018 Annual Meeting). The Company shall include the Amendments in its proxy statement for the 2018 Annual Meeting, and shall use its reasonable best
efforts (which shall include the solicitation of proxies) to cause the Amendments to be adopted by the Company’s stockholders by the appropriate vote. 

  

	 	7.	Voting of Investors’ Shares. In connection with any annual or special meeting of the stockholders of the Company (and any adjournments or postponements thereof) held prior to the Expiration
Date (as hereinafter defined), the Investors will cause to be present for quorum purposes and vote or cause to be voted all Voting Securities that they or their respective controlled Affiliates are entitled to vote as of the applicable record date,
in favor of, (A) the election of the Designees and any other directors who are nominated by the Board; and (B) otherwise in accordance with the Board’s recommendation on any proposal not related to (i) an Extraordinary
Transaction (as defined herein); (ii) any proposed issuance of shares of common stock, par value $0.01, of the Company (the “Common Stock”) or any securities convertible into, or exercisable or exchangeable for, Common Stock, in
each case, that requires a vote of the Company stockholders under NYSE Rule 312.03(c); (iii) any proposal by the Company to adopt any takeover defense measures or any other proposal by the Company that would diminish or otherwise impair in any
material respect the rights of Company stockholders or (iv) the issuance of at least fifteen percent (15%) of the Company’s equity or equity equivalent securities to a Third Party (including in a PIPE, convertible note, convertible
preferred security or similar structure). 

  

	 	8.	 Company Policies. The Investors acknowledge that each of the Designees, upon election or appointment to
the Board, will serve as a member of the Board and will be governed by the same protections and obligations regarding confidentiality, conflicts of interest, related party transactions, fiduciary duties, codes of conduct, trading and disclosure
policies, director resignation policy, and other governance guidelines and policies of the Company as other non-management directors (collectively, “Company Policies”) and shall be
required to preserve the confidentiality of the Company’s business and information, including discussions or matters considered in meetings of the Board or committees thereof in accordance with their respective fiduciary duties, applicable law
and applicable Company Policies, if any, and shall have the same rights and benefits, including 

  
 3 

	 	
with respect to insurance, indemnification, compensation and fees, as are applicable to all non-management directors of the Company. All Company Policies
in effect as of the date hereof are publicly available on the Company’s website or described in its proxy statement filed with the SEC on August 24, 2017, or have otherwise been provided to the Investors. The Company agrees that
(i) it will not amend any Company Policies in any manner for the purpose of disqualifying any Designee and (ii) any changes to the Company Policies, or new Company Policies, will be adopted in good faith and not for the purpose of
undermining or conflicting with the arrangements contemplated by this Agreement. 

  

	 	9.	Operating Improvement Committee. 

  

	 	a.	As promptly as practicable following the execution of this Agreement, the Board shall take all action necessary to form a committee of the Board to assist, advise and make recommendations to the Board on issues relating
to the Company’s operational and cost improvement initiatives and optimization (the “Operating Improvement Committee”). The Board shall cause the Operating Improvement Committee to adopt a charter (the “Operating
Improvement Committee Charter”), as promptly as practicable following its formation, in accordance with the terms set forth on Exhibit B attached hereto, and subject to the Investors’ reasonable consent. Once the Operating
Improvement Committee Charter is adopted, the Operating Improvement Committee Charter may not be amended prior to the Trigger Date without the prior written consent of the Investors (in their sole and absolute discretion). The Company shall cause
the Operating Improvement Committee to be comprised of not more than four (4) voting members from its formation until the Trigger Date and shall include the Company’s Chief Executive Officer as a
non-voting ex officio member. The four initial voting members shall consist of Thomas S. Gross, Robert A. Livingston and the Designees. For the avoidance of doubt, the Designees shall always be entitled
to act as members of the Operating Improvement Committee. Robert A. Livingston and Kirkland Andrews shall serve as co-chairs of the Operating Improvement Committee at all times prior to the Trigger Date.

  

	 	b.	The Operating Improvement Committee shall use reasonable best efforts to make the initial HPP Initiative Recommendation (as defined in Exhibit B) as soon as practicable, which the Board shall consider as soon as
practicable thereafter (and in any event no later than October 4, 2018). The Company shall finalize and announce the launch of the HPP Initiative no later than November 30, 2018 (such announcement, the “Launch
Announcement”). 

  
 4 

	 	10.	Private Communications; Confidentiality. Notwithstanding anything to the contrary contained in this Agreement, during the Restricted Period (as defined herein), the Investors and their respective Affiliates may
initiate and hold private communications regarding the Company and its Affiliates with the Board as a whole and/or any director without pre-approval or participation of any other director or any other
Person, in each case, only so long as such private communications do not violate the terms of this Agreement (including, without limitation, paragraph 12 hereof). Each of the Investors acknowledges and agrees that the directors may engage in
discussions with the Investors and their respective Affiliates only subject to, and in accordance with, their respective fiduciary duties and other obligations to the Company and the Company Policies. 

 

	 	11.	Press Releases; SEC Filings. Not later than 7:30 am ET on June 28, 2018, the Company shall issue a press release in the form attached hereto as Exhibit C (the “Company Press
Release”). Substantially concurrently with the release of the Company Press Release, the Company shall file a Current Report on Form 8-K, which shall be in form and substance reasonably acceptable to
the Company and the Investors. Neither of (i) the Company nor any of its Affiliates or Associates nor (ii) the Investors nor any of their Affiliates or Associates shall make any public statement regarding the subject matter of this
Agreement or the matters set forth in the Company Press Release prior to the issuance thereof. The Investors shall, and shall cause their respective Affiliates and Associates to, cause any public filings or public announcements that reference this
Agreement or the actions contemplated to be taken in connection with this Agreement or are otherwise made in connection therewith to be consistent with the Company Press Release and the terms of this Agreement. 

 

	 	12.	Standstill. From the date of this Agreement until the Expiration Date (such period, the “Restricted Period”), the Investors will not, and will cause their respective Affiliates and Associates and
their respective principals, directors, general partners, officers, employees, and agents and representatives acting on their behalf (collectively, the “Restricted Persons”) not to, directly or indirectly, alone or in concert with
others, absent prior express written invitation or authorization on behalf of the Board: 

  

	 	a.	engage in any “solicitation” (as such term is defined under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) of proxies or consents with respect to the election or removal
of directors or any other matter or proposal with respect to the Company or become a “participant” (as such term is defined in Instruction 3 to Item 4 of Schedule 14A promulgated under the Exchange Act) in any such solicitation of proxies
(including, without limitation, by initiating, encouraging or participating in any “withhold” or similar campaign); 

  

	 	b.	 knowingly encourage, advise, knowingly influence or instruct any Third Party or knowingly assist any Person in so
encouraging, advising, knowingly influencing or instructing any Third Party with respect to the giving or withholding of any proxy or other authority to vote, the voting or disposition of Voting Securities, or in conducting any type of referendum,
binding or non-binding, relating to the Company (other than such 

  
 5 

	 	
encouragement, advice or influence that is consistent with Company management’s recommendation in connection with such matter); provided that nothing in this clause (b) shall be
deemed to restrict the Investor or any of its Affiliates from acquiring any Voting Securities; 

  

	 	c.	form, join, act in concert, knowingly encourage or in any way participate with any partnership, limited partnership, syndicate or other group, including a “group” as defined pursuant to Section 13(d) of
the Exchange Act with respect to any Voting Securities, other than solely with other Affiliates (that are not portfolio companies) of the Investors with respect to Voting Securities now or hereafter owned by them; 

 

	 	d.	acquire, or offer, seek or agree to acquire, by purchase or otherwise, or direct any Third Party in the acquisition of, any securities (or any rights decoupled from the underlying securities) or assets of the Company,
or rights or options to acquire any securities (or rights decoupled from the underlying securities) or assets of the Company, or engage in any swap or hedging transactions or other derivative agreements of any nature with respect to securities (or
rights decoupled from the underlying securities) or assets of the Company, in each case, if such acquisition would result in the Investors having an aggregate beneficial ownership of ten percent (10%) or more of the then-outstanding Voting
Securities or economic exposure to fifteen percent (15%) or more of the then-outstanding Voting Securities; provided that nothing herein will require any Voting Securities to be sold solely to the extent that the Investors exceed the
ownership limit under this clause (d) as the result of a share repurchase or similar Company action that reduces the number of outstanding shares of any Voting Securities; 

 

	 	e.	engage in any short sale or any purchase, sale or grant of any option, warrant, convertible security, stock appreciation right, or other similar right (including any put or call option or “swap” transaction
with respect to any security (other than a broad-based market basket or index)) that includes, relates to or derives any significant part of its value from a decline in the market price or value of any securities of the Company if such short sale,
purchase, sale or grant would result in the Investors no longer having a net long position (as defined in Rule 14e-4 under the Exchange Act) in respect of the Common Stock; 

 

	 	f.	 initiate, effect or participate in any way in, or seek to offer or propose to effect, cause or participate in any
way in, any tender or exchange offer, merger, consolidation, acquisition, sale of all or substantially all assets or sale, spinoff, splitoff or other similar separation of one or more business units, scheme of arrangement, plan of arrangement,
business combination transaction, recapitalization, reorganization, liquidation, dissolution, issuance of at least fifteen percent (15%) of the Company’s equity or equity equivalent securities (including in a PIPE, convertible note, convertible
preferred security or similar structure) or other extraordinary 

  
 6 

	 	
transaction involving the Company or any of its subsidiaries or joint ventures or any of their respective securities or a material amount of any of their respective assets or businesses (each, an
“Extraordinary Transaction”); provided, however, that this clause (f) shall not restrict: (i) the tender (or failure to tender) by the Investor or any of its Affiliates of any securities of the Company into
any tender or exchange offer, (ii) the vote for or against any transaction by the Investor or any of its Affiliates of any securities of the Company with respect to any Extraordinary Transaction, or (iii) the receipt of any consideration
by the Investor or any of its Affiliates on the same basis as other stockholders of the Company in connection with an Extraordinary Transaction; 

  

	 	g.	enter into a voting trust, arrangement or agreement or subject any Voting Securities to any voting trust, arrangement or agreement, in each case other than solely with other Affiliates (that are not portfolio companies)
of the Investors, with respect to Voting Securities now or hereafter owned by them and other than granting proxies in solicitations approved by the Board; 

  

	 	h.	(i) seek, alone or in concert with others, election or appointment to, or representation on, the Board or nominate or propose the nomination of, or recommend the nomination of, any candidate to the Board (except as
set forth in paragraphs 1(b) and 3), (ii) request that, or knowingly encourage any Person to request that, the Company call any meeting of the stockholders (iii) seek, or knowingly encourage any Person to seek, the removal of any member of the
Board, (iv) conduct, or knowingly encourage any Person to conduct, a referendum of stockholders of the Company; or (v) present any matter at any meeting of stockholders of the Company; 

 

	 	i.	make or be the proponent of any stockholder proposal (pursuant to Rule 14a-8 under the Exchange Act, the By-Laws or otherwise);

  

	 	j.	make any request for stock list materials or other books and records of the Company under Section 220 of the Delaware General Corporation Law or other statutory or regulatory provisions providing for stockholder
access to books and records; 

  

	 	k.	make any public disclosure, communication, announcement or statement regarding any intent, purpose, plan or proposal with respect to the Board, the Company, its management, policies or affairs, any of its securities or
assets or this Agreement that is inconsistent with the provisions of this Agreement; 

  
 7 

	 	l.	take any action or make any public proposal or request with respect to: (i) controlling, changing or influencing the Board or management of the Company, including any plans or proposals relating to any change in
the number or term of directors or the filling of any vacancies on the Board, (ii) any material change in the capitalization, stock repurchase programs and practices, capital allocation programs and practices or dividend policy of the Company,
(iii) any other material change in the Company’s management, business, corporate or governance structure, (iv) any waiver, amendment or modification to the Certificate of Incorporation or the
By-Laws, or to other actions by the Company that may facilitate or impede the acquisition of control of the Company by any Person, (v) causing a class of securities of the Company to be delisted from, or
to cease to be authorized to be quoted on, any securities exchange or (vi) causing a class of equity securities of the Company to become eligible for termination of registration pursuant to Section 12(g)(4) of the Exchange Act;

  

	 	m.	institute, solicit, knowingly assist or join any litigation, arbitration or other proceeding against or involving the Company or any of its current, former or future directors or officers (including derivative actions);
provided, however, that for the avoidance of doubt the foregoing shall not prevent any Restricted Person from (i) bringing litigation to enforce the provisions of this Agreement instituted in accordance with and subject to this
paragraph 12, (ii) making counterclaims with respect to any proceeding initiated by, or on behalf of, the Company against a Restricted Person, (iii) bringing bona fide commercial disputes that do not relate to the subject matter of this
Agreement or (iv) exercising statutory appraisal rights; provided, further, that the foregoing shall also not prevent the Restricted Persons from responding to or complying with a validly issued legal process; 

 

	 	n.	make any public or private request or submit any proposal, directly or indirectly, to amend or waive the terms of this Agreement, in each case, which would reasonably be expected to require a public announcement of such
request or proposal; 

  

	 	o.	publicly disclose or otherwise make any public statement or announcement of any intention, purpose, plan or arrangement inconsistent with any provision of this paragraph 12; or 

 

	 	p.	enter into any negotiations, discussions, agreements or understandings with any Third Party to take any action with respect to any of the foregoing, or advise, facilitate, knowingly assist, finance, knowingly encourage
or seek to persuade any Third Party to take any action that the Investors are prohibited from taking pursuant to this paragraph 12; 

provided that (i) the restrictions in this paragraph 12 shall not prevent the Investor or any of its Affiliates from making
(1) any factual statement as required by applicable legal process, subpoena, or legal requirement from any governmental authority with competent jurisdiction over the party from whom information is sought (so long as such request did not arise
as a result of discretionary acts by the 

  
 8 

 
Investors or any of their respective Affiliates); (2) any confidential communication to the Company in accordance with paragraph 10, including the requirement therein that the communication not
be reasonably expected to require any public disclosure; (3) any public or private statement or announcement with respect to an Extraordinary Transaction that is publicly announced by the Company or a Third Party; (4) any public or private
statement or announcement after the Launch Announcement with respect to the process, findings or recommendations of the Operating Improvement Committee and the Board (including the final HPP Initiative Recommendation) with respect to the HPP
Initiative Recommendation, the HPP Initiative or the implementation thereof; and (5) any statement (whether positive or negative) that is in substance not inconsistent with this Agreement and the Press Release (or as otherwise consented to by
the Company, such consent not to be unreasonably withheld, conditioned or delayed) in response to any public statements by any other current or potential investor in the Company; and (ii) the restrictions in this paragraph 12 shall terminate
automatically upon the earliest of (A) the Expiration Date; (B) upon the announcement by the Company that it has entered into a definitive agreement with respect to any Extraordinary Transaction that would, if consummated, result in the
acquisition of beneficial ownership by any Person or group of Persons (other than any direct or indirect subsidiaries of the Company) of more than 50% of the Common Stock; (C) the commencement of any tender or exchange offer (by a Person other
than the Investors or their Affiliates) which, if consummated, would constitute an Extraordinary Transaction that would result in the acquisition of beneficial ownership by any person or group of more than 50% of the Common Stock, where the Company
files a Schedule 14D-9 (or any amendment thereto), other than a “stop, look and listen” communication by the Company pursuant to Rule 14d-9(f) promulgated
under the Exchange Act, that does not recommend that the Company’s stockholders reject such tender or exchange offer; and (D) any public statement or announcement by the Company with respect to the adoption or recommendation by the Board
of any amendment to the Certificate of Incorporation or By-Laws that would reasonably be expected to impair the ability of a stockholder to submit nominations for election to the Board or stockholder proposals
in connection with any future annual meeting of stockholders of the Company. 
  

	 	13.	 Non-Disparagement. During the Restricted Period, the Company and
the Investors shall each refrain from making, and shall cause their respective Affiliates and its and their respective principals, directors, members, general partners, officers and employees not to make or cause to be made any statement or
announcement, including in any document or report filed with or furnished to the SEC or through the press, media, analysts or other Persons, that constitutes an ad hominem attack on, or otherwise disparages, defames, slanders, impugns or is
reasonably likely to damage the reputation of, (a) in the case of statements or announcements by any of the Investors and their related Persons, the current, former or future officers, directors or employees of the Company or any of its
Affiliates or, prior to November 30, 2018, the Company or any of its Affiliates, and (b) in the case of statements or announcements by the Company and its 

  
 9 

	 	
related Persons, the Investors or any of the Investors’ advisors, their respective current, former or future officers, directors, employees, members or general partners. The foregoing shall
not (i) restrict the ability of any Person to comply with any subpoena or other legal process or respond to a request for information (provided that such request is not targeted at this Agreement or the other party hereto) from any governmental
authority with competent jurisdiction over the party from whom information is sought, (ii) apply to any private communications between the Investors, their respective Affiliates and its and their respective principals, directors, members,
general partners, officers and employees, on the one hand, and the directors of the Company, on the other hand, pursuant to paragraph 10 hereof to the extent that it would not be reasonably expected that such communication would require a public
disclosure, (iii) restrict the ability of the Investors and their related Persons to make any public or private statement or announcement after the Launch Announcement with respect to the process, findings or recommendations of the Operating
Improvement Committee and the Board (including the final HPP Initiative Recommendation), with respect to the HPP Initiative Recommendation, the HPP Initiative or the implementation thereof, or (iv) restrict the ability of the Investors and
their related Persons to make any statement in response to any criminal or civil investigation by any governmental authority related to the Company, its Affiliates, or any of its and their respective current, former or future officers, directors or
employees. 

  

	 	14.	Termination. The obligations of the Company under this Agreement shall terminate on the Trigger Date. The obligations of the Investors under this Agreement shall terminate on the Expiration Date. Termination of
obligations shall be without prejudice to any rights or remedies arising from breach of such obligations before such termination. 

  

	 	15.	Defined Terms. As used in this Agreement, 

  

	 	a.	“Affiliate” shall have the meaning set forth in Rule 12b-2 promulgated under the Exchange Act and shall include Persons who become Affiliates of any Person
subsequent to the date of this Agreement; provided that “Affiliates” of a Person shall not include any entity, solely by reason of the fact that one or more of such Person’s employees or principals serves as a member of its
board of directors or similar governing body, unless such Person otherwise controls such entity (as the term “control” is defined in Rule 12b-2 promulgated by the SEC under the Exchange Act);

  

	 	b.	“Associate” shall have the meaning set forth in Rule 12b-2 promulgated under the Exchange Act (provided, that the term “Associates” in such
definition shall be deemed to be preceded by the word “controlled”) and shall include Persons who become Associates of any Person subsequent to the date of this Agreement. 

  
 10 

	 	c.	“beneficial owner,” “beneficially own” and “beneficial ownership” shall have the respective meanings set forth in Rule 13d-3
(“Rule 13d-3”) promulgated by the SEC under the Exchange Act; 

  

	 	d.	“business day” shall mean any day other than a Saturday, Sunday or a day on which the Federal Reserve Bank of New York is closed; 

 

	 	e.	“economic owner,” “economically own” and “economic ownership” shall have the same meanings as “beneficial owner,” “beneficially own” and
“beneficial ownership” except that a Person will also be deemed to “economically own,” to be the “economic owner” and to have “economic ownership” of (i) all shares of Common Stock or other Voting
Securities which such Person has the right to acquire pursuant to the exercise of any rights in connection with any securities or any agreement, regardless of when such rights may be exercised and whether they are conditional, and (ii) all
shares of Common Stock or other Voting Securities in which such Person has an economic interest pursuant to a cash settled call option or other derivative security, contract or instrument related to the price of shares of Common Stock or other
Voting Securities (other than a broad-based market basket or index); 

  

	 	f.	“Expiration Date” means the date that is the earlier of (i) the fifth (5th) business day after written notice is delivered by the Investors to the Company of a material breach of this Agreement by
the Company if such breach has not been cured within such notice period; provided that no Investor is then in material breach of this Agreement (it being understood that occurrence of the Expiration Date shall be a non-exclusive remedy for such breach); (ii) the thirtieth (30th) day prior to the last day of the time period, established pursuant to the By-Laws, for stockholders to deliver
notice to the Company of director nominations to be brought before the Company’s 2019 Annual Meeting of Stockholders; and (iii) the failure of the Company to meet any of the deadlines set forth in paragraph 9(b) of this Agreement.

  

	 	g.	“Independent” means that a Person (x) (i) shall not be an employee, director, general partner, manager, advisor, representative, trustee, or other agent or fiduciary of an Investor or of any
Affiliate of an Investor, (ii) shall not be a limited partner, member or other investor in any Investor or any Affiliate (that is not a publicly traded portfolio company) of an Investor and (iii) shall not have any agreement, arrangement
or understanding, written or oral, with, or received or have any right to receive any payment from, an Investor or any Affiliate thereof in connection with such Designee’s agreement to serve or service on the Board, and (y) shall qualify
as an independent director of the Company under the Company’s independence guidelines applicable to non-management directors (as interpreted and determined by the Board), applicable law and the rules and
regulations of the SEC and the NYSE (or applicable requirements of such other national securities exchange designated as the primary market on which the Company’s Common Stock is listed for trading); 

  
 11 

	 	h.	“Person” shall be interpreted broadly to include, among others, any individual, general or limited partnership, corporation, limited liability or unlimited liability company, joint venture, estate,
trust, group, association or other entity of any kind or structure; 

  

	 	i.	“SEC” means the U.S. Securities and Exchange Commission; 

  

	 	j.	“Third Party” means any Person that is not (i) a party to this Agreement or an Affiliate thereof, (ii) a director or officer of the Company or (iii) legal counsel to any party to
this Agreement; 

  

	 	k.	“Trigger Date” means the date that is the earlier of (i) the fifth (5th) business day after written notice is delivered by the Company to the Investors of a material breach of this Agreement by the
Investors if such breach has not been cured within such notice period; provided that the Company is not then in material breach of this Agreement (it being understood that occurrence of the Trigger Date shall be a non-exclusive remedy for such breach) and (ii) the thirtieth (30th) day prior to the last day of the time period, established pursuant to the By-Laws, for stockholders to
deliver notice to the Company of director nominations to be brought before the Company’s 2019 Annual Meeting of Stockholders; and 

  

	 	l.	“Voting Securities” shall mean the shares of Common Stock and any other securities of the Company entitled to vote in the election of directors, or securities convertible into, or exercisable or
exchangeable for, such shares, whether or not subject to the passage of time or other contingencies. 

  

	 	16.	 Investors’ Representations and Warranties, Covenants. Each of the Investors represents and warrants
that (a) this Agreement has been duly authorized, executed and delivered by it and is a valid and binding obligation of such Investor, enforceable against it in accordance with its terms, except as enforcement thereof may be limited by
applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance or similar laws generally affecting the rights of creditors and subject to general equity principles; (b) each Investor has the power and authority to execute,
deliver and carry out the terms and provisions of this Agreement; (c) the execution and delivery by the Investors of this Agreement and the performance of the Investors’ obligations hereunder does not and will not violate any law, any
order of any court or other agency of government, the organizational documents of any Investor, or any provision of any agreement or other instrument to which any Investor or any of its properties or assets is bound, or conflict with, result in a
breach of or constitute (with due notice or lapse of time or both) a default under any such agreement or other 

  
 12 

	 	
instrument, or result in the creation or imposition of, or give rise to, any material lien, charge, restriction, claim, encumbrance or adverse penalty of any nature whatsoever pursuant to any
such indenture, agreement or other instrument; and (d) as of the date of this Agreement, each of the Investors and their Affiliates, beneficially owns or economically owns, directly or indirectly, such number of shares of Common Stock as
indicated on Exhibit D attached hereto, and such shares of Common Stock constitute all of the Common Stock beneficially or economically owned, as of the date of this Agreement, by any Investor and Affiliate thereof or in which any Investor or
Affiliate thereof has any interest or right to acquire or vote, whether through derivative securities, voting agreements or otherwise. 

  

	 	17.	Company Representations and Warranties. The Company represents and warrants that (a) this Agreement has been duly authorized, executed and delivered by it and is a valid and binding obligation of the
Company, enforceable against the Company in accordance with its terms, except as enforcement thereof may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance or similar laws generally affecting the
rights of creditors and subject to general equity principles; (b) it has the power and authority to execute, deliver and carry out the terms and provisions of this Agreement; (c) this Agreement does not require the approval of the
stockholders of the Company; (d) the execution and delivery by the Company of this Agreement and the performance of the Company’s obligations hereunder does not and will not violate any law, any order of any court or other agency of
government, the Certificate of Incorporation, the By-Laws or any provision of any agreement or other instrument to which the Company or any of its properties or assets is bound, or conflict with, result in a
breach of or constitute (with due notice or lapse of time or both) a default under any such agreement or other instrument, or result in the creation or imposition of, or give rise to, any material lien, charge, restriction, claim, encumbrance or
adverse penalty of any nature whatsoever pursuant to any such indenture, agreement or other instrument; and (e) the Company has not taken any actions that require disclosure on a Form 8-K prior to the
date of this Agreement that have not previously been disclosed. 

  

	 	18.	Affiliates. Each of the Investors agrees that it will cause its controlled Affiliates to comply with the terms of this Agreement. 

 

	 	19.	Specific Performance. The Company and each of the Investors each acknowledge and agree that money damages would not be a sufficient remedy for any breach (or threatened breach) of this Agreement by it and that,
in the event of any breach or threatened breach hereof, (a) the non-breaching party will be entitled to injunctive and other equitable relief, without proof of actual damages; (b) the breaching party
will not plead in defense thereto that there would be an adequate remedy at law; and (c) the breaching party agrees to waive any applicable right or requirement that a bond be posted by the non-breaching
party. Such remedies will not be the exclusive remedies for a breach of this Agreement, but will be in addition to all other remedies available at law or in equity. 

  
 13 

	 	20.	Entire Agreement; Successors and Assigns; Amendment and Waiver. This Agreement (including its exhibits and schedules) constitutes the only agreement between the Investors and the Company with respect to the
subject matter hereof and supersedes all prior agreements, understandings, negotiations and discussions, whether oral or written (except for any consent given prior to the date hereof). This Agreement shall be binding upon and inure to the benefit
of the parties and their respective successors and permitted assigns. No party may assign or otherwise transfer either this Agreement or any of its rights, interests, or obligations hereunder without the prior written approval of the other party.
Any purported transfer without such consent shall be void. No amendment, modification, supplement or waiver of any provision of this Agreement shall be effective unless it is in writing and signed by the party affected thereby, and then only in the
specific instance and for the specific purpose stated therein. Any waiver by any party of a breach of any provision of this Agreement shall not operate as or be construed to be a waiver of any other breach of such provision or of any breach of any
other provision of this Agreement. The failure of a party to insist upon strict adherence to any term of this Agreement on one or more occasions shall not be considered a waiver or deprive that party of the right thereafter to insist upon strict
adherence to that term or any other term of this Agreement. 

  

	 	21.	Severability. If any provision of this Agreement is held invalid or unenforceable by any court of competent jurisdiction, the other provisions of this Agreement shall remain in full force and effect. Any
provision of this Agreement held invalid or unenforceable only in part or degree shall remain in full force and effect to the extent not held invalid or unenforceable. The parties further agree to replace such invalid or unenforceable provision of
this Agreement with a valid and enforceable provision that will achieve, to the extent possible, the purposes of such invalid or unenforceable provision. 

  

	 	22.	 Governing Law; Jurisdiction. This Agreement shall be governed by and construed in accordance with the laws
of the State of Delaware. Each of the Investors and the Company (a) irrevocably and unconditionally consents to the personal jurisdiction and venue of the Delaware Court of Chancery (or, if the Delaware Court of Chancery declines to accept
jurisdiction over a particular matter, the federal or other state courts located in Wilmington, Delaware) and any appellate courts thereof; (b) agrees that it shall not attempt to deny or defeat such personal jurisdiction by motion or other
request for leave from any such court; (c) agrees that it shall not bring any action relating to this Agreement or the transactions contemplated by this Agreement in any court other than such courts; (d) waives any claim of improper venue
or any claim that those courts are an inconvenient forum and (e) agrees that a final judgment in any action or proceeding shall be conclusive and enforced in other jurisdictions by suit on the judgment or in any other manner provided by law.
The parties agree that mailing of process or other papers in connection with any such action or proceeding in the manner provided in paragraph 24 hereof or in such other manner as may be permitted by applicable law, shall be valid and sufficient
service thereof. Each of the parties hereto, after 

  
 14 

	 	
consulting or having had the opportunity to consult with counsel, knowingly, voluntarily, intentionally and irrevocably waives any right that such party may have to a trial by jury in any
litigation based upon or arising out of this Agreement or any related instrument or agreement, or any of the transactions contemplated thereby, or any course of conduct, dealing, statements (whether oral or written), or actions of any of them. No
party hereto shall seek to consolidate, by counterclaim or otherwise, any action in which a jury trial has been waived with any other action in which a jury trial cannot be or has not been waived. 

 

	 	23.	Parties in Interest. This Agreement is solely for the benefit of the parties hereto and is not binding upon (other than successors to the parties hereto) or enforceable by any other Persons. No party to this
Agreement may assign its rights or delegate its obligations under this Agreement, whether by operation of law or otherwise, and any assignment in contravention hereof shall be null and void. Nothing in this Agreement, whether express or implied, is
intended to or shall confer any rights, benefits or remedies under or by reason of this Agreement on any Persons other than the parties hereto, nor is anything in this Agreement intended to relieve or discharge the obligation or liability of any
Third Party to any party hereto. 

  

	 	24.	Notices. All notices, consents, requests, instructions, approvals and other communications provided for herein, and all legal process in regard hereto, will be in writing and will be deemed validly given, made or
served when delivered in person, by electronic mail, by overnight courier or two business days after being sent by registered or certified mail (postage prepaid, return receipt requested) as follows: 

 

			
	If to the Company to:
	
	 RPM International Inc.
 2628 Pearl
Road, P.O. Box 777

	Medina, Ohio 44258
	Attn:	  	General Counsel and Chief Compliance Officer
	E-mail:	  	emoore@rpminc.com
	
	with a copy (which shall not constitute notice) to:
	
	 Simpson Thacher & Bartlett LLP

425 Lexington Avenue

	New York, NY 10017
	Attn:	  	Mario Ponce
		  	Eric Swedenburg
	E-mail:	  	mponce@stblaw.com; eswedenburg@stblaw.com
	
	If to the Investors:
	
	Elliott Associates, L.P.
	Elliott International, L.P.

  
 15 

			
	 Elliott International Capital Advisors Inc.

40 West 57th Street

	New York, New York 10019
	Attn:	  	Jesse A. Cohn; Jeffrey Rosenbaum
	E-mail:	  	jcohn@elliottmgmt.com; jrosenbaum@elliottmgmt.com
	
	with a copy (which shall not constitute notice) to:
	
	 Akin Gump Strauss Hauer & Feld LLP

1 Bryant Park

	New York, NY 10036
	Attn:	  	Jeffrey L. Kochian
	E-mail:	  	jkochian@akingump.com

 At any time, any party hereto may, by notice given in accordance with this paragraph 24 to the other
party, provide updated information for notices hereunder. 
  

	 	25.	Expenses. All attorneys’ fees, costs and expenses incurred in connection with this Agreement and all matters related hereto will be paid by the party incurring such fees, costs or expenses.

  

	 	26.	 Interpretation. When a reference is made in this Agreement to a paragraph, such reference shall be to a
paragraph of this Agreement, unless otherwise indicated. The headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. Whenever the words
“include,” “includes” and “including” are used in this Agreement, they shall be deemed to be followed by the words “without limitation.” The words “hereof,” “herein” and
“hereunder” and words of similar import when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The word “will” shall be construed to have the same meaning as
the word “shall.” The words “date hereof” will refer to the date of this Agreement. The word “or” is not exclusive. The definitions contained in this Agreement are applicable to the singular as well as the plural forms
of such terms. Any agreement, instrument, law, rule or statute defined or referred to herein means, unless otherwise indicated, such agreement, instrument, law, rule or statute as from time to time amended, modified or supplemented. Each of the
parties acknowledges that it has been represented by counsel of its choice throughout all negotiations that have preceded the execution of this Agreement, and that it has executed this Agreement with the advice of such counsel. Each party hereto and
its counsel cooperated and participated in the drafting and preparation of this Agreement, and any and all drafts relating thereto exchanged among the parties shall be deemed the work product of all of the parties and may not be construed against
any party by reason of its drafting or preparation. Accordingly, any rule of law or any legal decision that would require interpretation of any ambiguities in this Agreement against any party that drafted or prepared it is of no application and is
hereby expressly waived by each of the 

  
 16 

	 	
parties, and any controversy over interpretations of this Agreement shall be decided without regard to events of drafting or preparation. Notwithstanding anything contained in the definitions of
“Affiliate” or “Associates” to the contrary, for purposes of this Agreement (i) the covenants applicable to each Investor as set forth in this Agreement shall only require such Investor to cause its portfolio companies to
take or refrain from taking action to the extent such Investor has a contractual, legal or other right or ability to cause such portfolio company to take or refrain from taking such action (provided that it shall also constitute a breach of any such
covenant for any Investor to request, instruct or direct any of its portfolio companies to take any action or fail to take any action which action or failure to act would if taken by such Investor constitute a breach of this Agreement) and
(ii) the representations and warranties applicable to each Investor as set forth in this Agreement shall only be made to the knowledge of such Investor to the extent such representations and warranties relate to the portfolio companies of such
Investor. 

  

	 	27.	Counterparts. This Agreement may be executed by the parties in separate counterparts (including by fax, jpeg, .gif, .bmp and .pdf), each of which when so executed shall be an original, but all such counterparts
shall together constitute one and the same instrument. This Agreement shall become effective when one or more counterparts have been signed by each of the parties hereto and delivered (which delivery may be physically, by facsimile, e-mail or by other electronic means) to the other parties hereto. 

 [Signature page
follows] 

  
 17 

 If the terms of this Agreement are in accordance with your understanding, please sign below,
whereupon this Agreement shall constitute a binding agreement among us. 
  

			
	Very truly yours,
	
	RPM INTERNATIONAL INC.
		
	By:	 	 /s/ Frank C. Sullivan

		 	Name: Frank C. Sullivan
		 	Title: Chairman and CEO

 [Signature Page to Cooperation Agreement] 

 Accepted and agreed to as of the date first written above: 

 

					
	ELLIOTT ASSOCIATES, L.P.
		
	By:	 	Elliott Capital Advisors, L.P., as General Partner
		
	By:	 	Braxton Associates, Inc., as General Partner
		
	By:	 	 /s/ Joshua Nadell

		 	Name:	 	Joshua Nadell
		 	Title:	 	Vice President
	
	ELLIOTT INTERNATIONAL, L.P.
		
	By:	 	Elliott Capital Advisors, L.P., as General Partner
		
	By:	 	Braxton Associates, Inc., as General Partner
		
	By:	 	 /s/ Joshua Nadell

		 	Name:	 	Joshua Nadell
		 	Title:	 	Vice President
	
	ELLIOTT INTERNATIONAL CAPITAL ADVISORS INC.
		
	By:	 	 /s/ Joshua Nadell

		 	Name:	 	Joshua Nadell
		 	Title:	 	Vice President

 [Signature Page to Cooperation Agreement]Exhibit 10.1

 

NORTHWEST BIOTHERAPEUTICS,
INC.

 

FORM OF SECURITIES PURCHASE
AGREEMENT

  

 

This
Securities Purchase Agreement (this “Agreement”) is made and entered into as of                        ,
2018 (the “Effective Date”), by and between Northwest Biotherapeutics, Inc.,
a Delaware Corporation (the “Company”) and the purchasers signatory hereto (each a “Purchaser”
and together, the “Purchasers”).

 

Recitals

 

Whereas,
subject to the terms and conditions set forth in this Agreement and pursuant to an effective S-3 registration statement under the
Securities Act of 1933, as amended (the “Securities Act”), the Company desires to issue and sell to each
Purchaser, and each Purchaser, severally, desires to purchase from the Company, securities of the Company as more fully described
in this Agreement;

 

Whereas,
the Company desires to issue and sell shares of common stock of the Company (the “Common Stock”) and
two-year Class D-3 Warrants (the “Warrants”, and together with the Common Stock, the “Offered
Securities”), and has authorized such sale and issuance; and

 

Whereas,
each Purchaser desires to purchase the Offered Securities from the Company on the terms and conditions set forth herein;

 

Agreement

 

Now,
Therefore, in consideration of the foregoing recitals and the mutual promises, representations, warranties, and covenants
hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,
the parties hereto agree as follows:

 

1. Agreement
To Sell And Purchase.

 

The Purchasers severally
hereby agree to purchase, and the Company hereby agrees to sell and issue to the Purchasers for an aggregate of One Million Dollars
($1,000,000) (the “Purchase Price”), 4,000,000 shares of Common Stock of the Company (the “Shares”),
at a purchase price of $0.25 per share and 2,000,000 Warrants, with an exercise price of $0.30 per share of Common Stock. The Company
has authorized the sale and issuance of the Offered Securities to the Purchaser.

 

    	 	 

     

    

 

2. Closing,
Delivery And Payment.

 

The closing of the
sale and purchase of the Offered Securities under this Agreement will take place on June 22, 2018 or at such other time or place
as the Company and the Purchaser may mutually agree. At the closing of this offering (the “Closing”),
the Company will cause to be delivered to the Purchaser a DRS book entry statement representing the Shares, against payment of
the applicable purchase price by wire transfer of immediately available funds to such account as may be designated by the Company
and the Warrant being purchased by the Purchaser in the form attached hereto as Exhibit A.

 

3. Representations
and Warranties of the Company.

 

The Company hereby
represents and warrants to the Purchaser that as of the Closing hereunder:

 

(a) The Company
is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has all necessary
corporate power and authority to (i) own, operate and occupy its properties and to carry on its business as presently conducted
and (ii) enter into this Agreement and the other agreements, instruments and documents contemplated hereby, and to consummate the
transactions contemplated hereby and thereby. The Company is qualified to do business and is in good standing in each jurisdiction
in which the failure to so qualify would have a material adverse effect on the Company.

 

(b) All necessary
corporate proceedings, votes, resolutions and approvals relating to the issuance and sale of the Offered Securities will have been
completed by the Company. Upon execution, this Agreement will constitute a valid and legally binding obligation of the Company,
enforceable in accordance with its terms except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium,
and other laws of general application affecting enforcement of creditors’ rights generally, and (ii) as limited by laws relating
to the availability of specific performance, injunctive relief or other equitable remedies.

 

(c) The Shares purchased pursuant
to this Agreement, will be, upon payment by the Purchaser in accordance with this Agreement, duly authorized, validly issued, fully
paid and non-assessable.

 

(d) The Warrants are valid and
binding obligations of the Company, and when the shares underlying the Warrants have been paid for as provided in the Warrant,
then the underlying shares of common stock will be duly authorized, validly issued, fully paid and non-assessable.

 

4. Representations
and Warranties of the Purchaser. 

 

Each Purchaser hereby
represents and warrants to the Company that as of the Closing hereunder:

 

(a) The Purchaser
has full power and authority to enter into this Agreement. Upon execution, this Agreement will constitute a valid and legally binding
obligation of the Purchaser, enforceable in accordance with its terms except (i) as limited by applicable bankruptcy, insolvency,
reorganization, moratorium, and other laws of general application affecting enforcement of creditors’ rights generally, and
(ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies.

 

    	 	 

     

    

 

(b) At the
time the Purchaser was offered the Offered Securities, it was (i) an “accredited investor” within the
meaning of Rule 501(a) of Regulation D promulgated under the Securities Act or (ii) a “qualified institutional buyer”
as defined in Rule 144A(a) under the Securities Act.

 

(c) The Purchaser,
either alone or together with its representatives, has such knowledge, sophistication and experience in business and financial
matters so as to be capable of evaluating the merits and risks of the prospective investment in the Offered Securities, and has
so evaluated the merits and risks of such investment.

 

(d) The Purchaser
is an experienced investor in securities of companies in the development stage, can bear the economic risk of its investment, including
a total loss, and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits
and risks of the investment in the Offered Securities. The Purchaser has conducted its own due diligence review of the Company
and received copies or originals of all documents it has requested from the Company.

 

5. Miscellaneous.

 

5.1 Governing
Law. This Agreement will be governed by and construed in accordance with the laws of the State of Delaware, without regard
to principles of conflicts of law. The parties hereby agree that any legal action, suit or proceeding arising out of or relating
to this Agreement will be brought in federal or state court located in Delaware.

 

5.2 Entire
Agreement; Amendments. This Agreement constitutes the full and entire understanding and agreement between the parties with
regard to the subjects hereof and thereof. Except as otherwise expressly provided herein, neither this Agreement nor any term hereof
or thereof may be amended, waived, discharged or terminated, except by a written instrument signed by the Company and a majority
of the Purchasers.

 

5.3 Notices.
Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement must
be in writing and will be deemed to be effective upon delivery when delivered (a) personally; (b) by facsimile, provided a positive
transmission report is received and a copy is mailed no later than the next business day through a nationally recognized overnight
delivery service; (c) by overnight delivery with a nationally recognized overnight delivery service, in each case properly addressed
to the party to receive the same. The addresses and facsimile numbers for such communications will be,

 

in the case of the Purchaser
as set forth on the signature pages hereto,

 

    	 	 

     

    

 

and in the case of the Company:

 

Leslie J. Goldman

Senior Vice President

Northwest Biotherapeutics

4800 Montgomery Lane

Suite 800

Bethesda, MD 20814

email: lgoldman@nwbio.com

 

or at such other address and facsimile
number as the receiving party will have furnished to the sending party in writing.

 

5.4 Severability.
The representations, warranties, covenants and agreements made and incorporated by reference herein will survive any investigation
made by or on behalf of the Purchaser or the Company, and will survive for two years after the Effective Date.

 

5.5 Successors
and Assigns. Except as otherwise expressly provided herein, the provisions hereof will inure to the benefit of, and be binding
upon, the respective successors, assigns, heirs, executors and administrators of the parties hereto. The Purchaser may transfer
or assign all or any portion of its rights under this Agreement to any person or entity permitted under applicable securities laws.

 

5.6 Interpretations.
All pronouns and any variations thereof will be deemed to refer to the masculine, feminine, neuter, singular or plural, as the
identity of the person or persons or entity or entities may require. All references to “$” or dollars herein will be
construed to refer to United States dollars. The titles of the Sections and subsections of this Agreement are for convenience or
reference only and are not to be considered in construing this Agreement. All references to “including” shall be deemed
to mean “including, without limitation.”

 

5.7 Severability.
In case any provision of this Agreement is determined to be invalid, illegal or unenforceable, the validity, legality and enforceability
of the remaining provisions will not in any way be affected or impaired thereby.

 

5.8 Counterparts.
This Agreement may be executed in counterparts, each of which when so executed and delivered will constitute a complete and original
instrument but all of which together will constitute one and the same agreement, and it will not be necessary when making proof
of this Agreement or any counterpart thereof to account for any counterpart other than the counterpart of the party against whom
enforcement is sought.

 

 

[Remainder of Page Intentionally Left
Blank] 

 

    	 	 

     

    

 

In
Witness Whereof, the parties hereto have executed this Common
Stock Purchase Agreement as of the date set forth in the first paragraph hereof.

 

 

	
        COMPANY:

        
	 	 
	Northwest Biotherapeutics, Inc.	 
	 	 	 
	 	 	 
	 	 	 
	By: Northwest Biotherapeutics	 	 
	 	 	 
	Name:  Leslie J. Goldman	 	 
	 	 	 
	Title: Senior Vice President	 	 
	 	 	 
	 	 	 
	PURCHASER:	 	 
	 	 	 
	 	 	 
	 	 	 
	By:  	 	 
	 	 	 
	Name:	 	 
	 	 	 
	Title: 	 	 

 

 

 

[NWBO Securities Purchase
Agreement - Signature Page]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}]]